Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours

[1]  K. Do,et al.  A 20% dose reduction of the original CISCA/VB regimen allows better tolerance and similar survival rate in disseminated testicular non-seminomatous germ-cell tumors: final results of a phase III randomized trial. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  C. Logothetis,et al.  Germ cell tumors in patients infected by the human immunodeficiency virus , 2001, Cancer.

[3]  R. Motzer,et al.  Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  C. Meisner,et al.  Identification of prognostic subgroups among patients with metastatic 'IGCCCG poor-prognosis' germ-cell cancer: an explorative analysis using cart modeling. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  S. Culine,et al.  The growing teratoma syndrome: results of therapy and long-term follow-up of 33 patients. , 2000, European journal of cancer.

[6]  H. Fukuda,et al.  European Organization for Research and Treatment of Cancer (EORTC) and International Society for Cutaneous Lymphoma (ISCL) consensus recommendations for the management of cutaneous B-cell lymphomas Blood 2008; 112(5):1600-9 , 2022 .

[7]  L. Zelek,et al.  Is òne cycle every three or four weeks' obsolete? A critical review of dose-dense chemotherapy in solid neoplasms. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  C. Meisner,et al.  First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  J. Tabernero,et al.  BOMP/EPI intensive alternating chemotherapy for IGCCC poor-prognosis germ-cell tumors: the Spanish Germ-Cell Cancer Group experience (GG) , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  L. Collette,et al.  Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of Cancer. , 1998, British Journal of Cancer.

[11]  P. Catalano,et al.  Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  R Sylvester,et al.  Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of Cancer study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  E. Cvitkovic.  Bleomycin in nonseminomatous germ-cell tumors: cure rate versus morbidity. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  S. Culine,et al.  Primary mediastinal nonseminomatous germ cell tumors: results of modern therapy including cisplatin-based chemotherapy. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  R H Begent,et al.  Treatment of men with metastatic non-seminomatous germ cell tumours with cyclical POMB/ACE chemotherapy. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  P. Wilkinson,et al.  International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  S. Culine,et al.  Chemotherapy in adult germ cell tumors. , 1996, Critical reviews in oncology/hematology.

[18]  L. Einhorn,et al.  Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  W. Siegert,et al.  Cisplatin, etoposide, ifosfamide, vincristine and bleomycin combination chemotherapy for far advanced testicular carcinoma. , 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  S. Fosså,et al.  Original article: BOP/VIP - A new platinum-intensive chemotherapy regimen for poor prognosis germ cell tumours , 1991 .

[21]  N. Geller,et al.  Serum tumor marker half-life during chemotherapy allows early prediction of complete response and survival in nonseminomatous germ cell tumors. , 1990, Cancer research.

[22]  R. Simon,et al.  Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.

[23]  W. M. Linehan,et al.  A randomized trial of standard chemotherapy v a high-dose chemotherapy regimen in the treatment of poor prognosis nonseminomatous germ-cell tumors. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  L. Einhorn,et al.  Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. , 1987, The New England journal of medicine.

[25]  C. Logothetis,et al.  Cyclic chemotherapy with cyclophosphamide, doxorubicin, and cisplatin plus vinblastine and bleomycin in advanced germinal tumors. Results with 100 patients. , 1986, The American journal of medicine.

[26]  C. Logothetis,et al.  Improved survival with cyclic chemotherapy for nonseminomatous germ cell tumors of the testis. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  E. Gehan,et al.  Dose‐response and dose‐survival advantage for high versus low‐dose cisplatin combined with vinblastine and bleomycin in disseminated testicular cancer a southwest oncology group study , 1984, Cancer.

[28]  W. Robinson,et al.  Vincristine, cisplatin, and bleomycin with surgery in the management of advanced metastatic nonseminomatous testis tumors , 1984, Cancer.

[29]  R. Golbey,et al.  High dose Cis‐platinum diammine dichloride. Amelioration of renal toxicity by mannitol diuresis , 1977, Cancer.

[30]  C. Bokemeyer,et al.  Treatment of testicular cancer and the development of secondary malignancies. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  A. Horwich,et al.  Prognostic significance of early serum tumor marker half-life in metastatic testicular teratoma. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  R. Ravi.  Growing teratoma syndrome. , 1995, Urologia internationalis.

[33]  A. Horwich,et al.  Accelerated chemotherapy for poor prognosis germ cell tumours. , 1994, European journal of cancer.

[34]  P. Biron,et al.  Early intensified chemotherapy with autologous bone marrow transplantation in first line treatment of poor risk non-seminomatous germ cell tumours. Preliminary results of a French randomized trial. , 1993, European urology.

[35]  C. Tangen,et al.  A Southwest Oncology Group study , 1993 .

[36]  H. Villavicencio,et al.  Intensive chemotherapy in poor-prognosis nonseminomatous germ cell tumors of the testis. , 1992, European urology.

[37]  S. Fosså,et al.  BOP/VIP--a new platinum-intensive chemotherapy regimen for poor prognosis germ cell tumours. , 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

[38]  J. Droz,et al.  [Value of high-dose chemotherapy followed by bone marrow autograft in non-seminomatous germinal tumor with poor prognosis. Results of the combination of cisplatinum, etoposide and cyclophosphamide (PEC protocol)]. , 1990, Bulletin du cancer.